-
2024-515658-26-00
5
2026-01-21
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
-
2025-521917-24-00
5
2026-01-21
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
-
2025-522307-14-00
2
2026-01-19
Melanoma
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2024-520164-33-00
5
2025-12-09
Non-Small Cell Lung Cancer
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2025-521381-10-00
5
2025-12-03
Moderately to Severely Active Ulcerative Colitis
-
2024-519871-24-00
10
2025-11-11
Breast cancer
-
2024-519420-25-00
5
2025-10-22
Major Depressive Disorder
-
2024-519883-42-00
5
2025-10-08
Non-small cell lung cancer
-
2024-517232-22-00
5
2025-09-26
KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorect
-
2024-520210-21-00
5
2025-09-19
Crohn’s Disease
-
2024-517780-24-00
5
2025-09-18
Lung Cancer
-
2024-519814-29-00
4
2025-09-12
Advanced or Metastatic Non-small Cell Lung Cancer
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-519525-38-00
5
2025-08-22
Heart failure
-
2023-509630-19-00
5
2025-07-31
Esophageal Squamous Cell Carcinoma (ESCC)
-
2023-503634-50-01
5
2025-07-22
Anemia in patients with chronic kidney disease on dialysis
-
2024-517991-39-00
5
2025-07-22
Asthma
-
2024-519059-28-00
5
2025-07-17
Chronic Heart Failure
-
2024-515884-69-00
5
2025-07-16
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
-
2024-516834-36-00
5
2025-07-08
Locally recurrent unresectable or metastatic TNBC with tumors expressi
-
2024-513682-40-01
5
2025-07-04
Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer
-
2024-516633-12-00
5
2025-06-30
Locally advanced/ metastatic gastroesophageal junction and gastric can